公开(公告)号：US10654913B2

公开(公告)日：2020-05-19

申请号：US16032691

申请日：2018-07-11

Applicant: Janssen Biotech, Inc.

Inventor： Steven Jacobs ,  Karyn O'Neil

IPC: C40B40/10 ,  C07K14/78 ,  C40B50/06 ,  C40B40/08

Abstract: A protein scaffold based on a consensus sequence of fibronectin type III (FN3) proteins, such as the tenth FN3 repeat from human fibronectin (human Tenascin), including isolated nucleic acids that encode a protein scaffold, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices. In particular, protein scaffold molecules binding to IgG have been identified as useful for diagnostic and/or therapeutic applications.

公开(公告)号：US20190263915A1

公开(公告)日：2019-08-29

申请号：US16227597

申请日：2018-12-20

Applicant: Janssen Biotech, Inc.

Inventor： Shalom GOLDBERG ,  Steven JACOBS ,  Tricia LIN ,  Karyn O'Neil

IPC: C07K16/28 ,  G01N33/74 ,  C07K14/78

Abstract: Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.

公开(公告)号：US20190184028A1

公开(公告)日：2019-06-20

申请号：US16218990

申请日：2018-12-13

Applicant: Janssen Biotech, Inc.

Inventor： Vadim Dudkin ,  Andrew Elias ,  Shalom Goldberg ,  Donna Klein ,  Elise Kuhar ,  Tricia Lin ,  Lavanya Peddada ,  Karyn O'Neil ,  Kristen Wiley

IPC: A61K47/68 ,  A61P35/00 ,  C07K14/78 ,  A61P37/06 ,  B82Y5/00 ,  A61K47/69 ,  A61K47/64 ,  A61K47/42 ,  A61K31/7105

CPC classification number: A61K47/6807 ,  A61K31/7105 ,  A61K47/42 ,  A61K47/6415 ,  A61K47/6925 ,  A61K47/6929 ,  A61P35/00 ,  A61P37/06 ,  B82Y5/00 ,  C07K14/78

Abstract: A fibronectin type III (FN3) domain-nanoparticle or direct conjugate complex containing a polynucleotide molecule, a toxin, polynucleotide molecule or other pharmaceutically active payload is obtained by panning an FN3 domain library with a protein or nucleotide of interest, recovering the FN3 domain and conjugating the FN3 domain with a toxin or nanoparticle containing an active polynucleotide, such as an ASO or siRNA molecule. A fibronectin type III (FN3) domain-nucleic acid conjugate is obtained by panning an FN3 domain library with a protein or nucleotide of interest, recovering the FN3 domain and conjugating the FN3 domain to a nucleic acid (e.g., ASO or siRNA). The nanoparticle complex, nucleic acid conjugate or FN3 domain toxin conjugate may be used in the treatment of diseases and conditions, for example, oncology or auto-immune indications.

公开(公告)号：US20170348397A1

公开(公告)日：2017-12-07

申请号：US15611296

申请日：2017-06-01

Applicant: Janssen Biotech, Inc.

Inventor： Michael Diem ,  Steven Jacobs ,  Karyn O'Neil ,  Thomas Rutkoski

IPC: A61K38/39 ,  C07K16/40 ,  C07K14/78 ,  C07K16/18

CPC classification number: A61K38/39 ,  A61K47/549 ,  A61K2039/505 ,  C07K14/78 ,  C07K16/18 ,  C07K16/40 ,  C07K2317/94 ,  C07K2318/20 ,  C07K2319/30 ,  C07K2319/31 ,  C07K2319/70

Abstract: Fibronectin type III domains (FN3) that specifically bind to serum albumin, related polynucleotides capable of encoding serum albumin-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, detectably labeled FN3 domains and FN3 domains fused to a heterologous moiety are useful in extending the half-life of molecules in diagnostic and therapeutic applications.

公开(公告)号：US20140155325A1

公开(公告)日：2014-06-05

申请号：US14085340

申请日：2013-11-20

Applicant: Janssen Biotech, Inc.

Inventor： Anderson Mark ,  Ricardo Attar ,  Michael Diem ,  Linus Hyun ,  Steven Jacobs ,  Alastair King ,  Donna Klein ,  Sheri Moores ,  Karyn O'Neil ,  Kristen Picha

IPC: C07K14/78 ,  A61K45/06 ,  A61K38/39

CPC classification number: C07K14/78 ,  A61K38/00 ,  A61K45/06 ,  A61K2039/505 ,  C07K14/47 ,  C07K14/705 ,  C07K14/71 ,  C07K16/28 ,  C07K16/2863 ,  C07K2317/31 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2318/20 ,  C07K2319/70

Abstract: Monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.